Mariana Teixeira Santos Figueiredo Salgado, Mayara Cristini Sebastião Silva, Ricardo Correia da Silva, Maria Luísa Arantes Campos, Camilly Fratelli, Anna Rafaela Cavalcante Braga, Milena Barcza Stockler-Pinto, Ana Paula de Souza Votto, Luciana Souza de Paiva
{"title":"C-phycocyanin acts as a positive immunomodulator in different primary and secondary organs of mice.","authors":"Mariana Teixeira Santos Figueiredo Salgado, Mayara Cristini Sebastião Silva, Ricardo Correia da Silva, Maria Luísa Arantes Campos, Camilly Fratelli, Anna Rafaela Cavalcante Braga, Milena Barcza Stockler-Pinto, Ana Paula de Souza Votto, Luciana Souza de Paiva","doi":"10.1080/08923973.2024.2448801","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objective:</b> C-Phycocyanin (C-PC) is a photosynthetic pigment with interesting therapeutic properties. However, its effectiveness in modulating the immune system cell populations has not been elucidated. We analyzed the action of C-PC on the modulation of mice immune system.</p><p><p><b>Methods:</b> The animals were treated subcutaneously with C-PC for 3 consecutive days. On the fourth day, the animals were euthanized and cells from different organs were analyzed by flow cytometry. Cytotoxicity was analyzed using biochemical parameters.</p><p><p><b>Results:</b> The results showed that C-PC increased the total cellularity in percentage and absolute number in the inguinal lymph node as well as the absolute number of B cells, CD4+ and CD8+ T cells and myeloid cells. The percentage of B cells was also increased in the lymph node. In the bone marrow, there was a reduction in immature and mature B cells. In contrast, C-PC increased the percentage and absolute number of myeloid cells in the bone marrow. C-PC administration also promoted an increase of CD4+ and CD8+ T cells in the thymus, and a reduction in these populations in the spleen.</p><p><p><b>Conclusion:</b> The data show for the first time the positive immunomodulatory role of C-PC by recruiting distinct populations of immune system cells to the treatment-draining lymphoid organ.</p>","PeriodicalId":13420,"journal":{"name":"Immunopharmacology and Immunotoxicology","volume":" ","pages":"1-12"},"PeriodicalIF":2.9000,"publicationDate":"2025-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunopharmacology and Immunotoxicology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08923973.2024.2448801","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: C-Phycocyanin (C-PC) is a photosynthetic pigment with interesting therapeutic properties. However, its effectiveness in modulating the immune system cell populations has not been elucidated. We analyzed the action of C-PC on the modulation of mice immune system.
Methods: The animals were treated subcutaneously with C-PC for 3 consecutive days. On the fourth day, the animals were euthanized and cells from different organs were analyzed by flow cytometry. Cytotoxicity was analyzed using biochemical parameters.
Results: The results showed that C-PC increased the total cellularity in percentage and absolute number in the inguinal lymph node as well as the absolute number of B cells, CD4+ and CD8+ T cells and myeloid cells. The percentage of B cells was also increased in the lymph node. In the bone marrow, there was a reduction in immature and mature B cells. In contrast, C-PC increased the percentage and absolute number of myeloid cells in the bone marrow. C-PC administration also promoted an increase of CD4+ and CD8+ T cells in the thymus, and a reduction in these populations in the spleen.
Conclusion: The data show for the first time the positive immunomodulatory role of C-PC by recruiting distinct populations of immune system cells to the treatment-draining lymphoid organ.
期刊介绍:
The journal Immunopharmacology and Immunotoxicology is devoted to pre-clinical and clinical drug discovery and development targeting the immune system. Research related to the immunoregulatory effects of various compounds, including small-molecule drugs and biologics, on immunocompetent cells and immune responses, as well as the immunotoxicity exerted by xenobiotics and drugs. Only research that describe the mechanisms of specific compounds (not extracts) is of interest to the journal.
The journal will prioritise preclinical and clinical studies on immunotherapy of disorders such as chronic inflammation, allergy, autoimmunity, cancer etc. The effects of small-drugs, vaccines and biologics against central immunological targets as well as cell-based therapy, including dendritic cell therapy, T cell adoptive transfer and stem cell therapy, are topics of particular interest. Publications pointing towards potential new drug targets within the immune system or novel technology for immunopharmacological drug development are also welcome.
With an immunoscience focus on drug development, immunotherapy and toxicology, the journal will cover areas such as infection, allergy, inflammation, tumor immunology, degenerative disorders, immunodeficiencies, neurology, atherosclerosis and more.
Immunopharmacology and Immunotoxicology will accept original manuscripts, brief communications, commentaries, mini-reviews, reviews, clinical trials and clinical cases, on the condition that the results reported are based on original, clinical, or basic research that has not been published elsewhere in any journal in any language (except in abstract form relating to paper communicated to scientific meetings and symposiums).